Emily's Entourage
Michael Golinkoff, PhD, MBA currently serves as an advisor for several companies in the healthcare and technology sectors. With a background in clinical and developmental psychology, as well as business, Michael has held various leadership positions in organizations focused on improving behavioral health care services for different populations. As the President and Co-Founder of Emily's Entourage, Michael has shown a dedication to addressing the needs of individuals with medical conditions and severe mental illnesses. Through his roles as Chief Clinical Officer and President of PerformCare (CBHNP), Michael has played key roles in managing large behavioral health organizations and developing integrated care management programs. His expertise in enterprise analytics and business development has been instrumental in informing strategic priorities and driving innovation in healthcare services. As a Board Chair and advisor for various companies, Michael continues to contribute his knowledge and leadership to advance the next generation of healthcare solutions.
This person is not in any teams
Emily's Entourage
Emily's Entourage (EE) is an innovative 501(c)3 foundation that funds research for new treatments and a cure for individuals in the final 10% of the cystic fibrosis (CF) community that do not benefit from existing mutation-targeted therapies, including those with nonsense mutations. CF is a fatal genetic disease primarily affecting the lungs and digestive system. Founded by Emily Kramer-Golinkoff, a woman with advanced stage CF, and her devoted friends and family, the organization has been featured in national media, including the New York Times, STAT, CNN, People, and more. Since 2011, Emily’s Entourage has awarded millions of dollars in research grants, launched a now-acquired CF gene therapy company, developed a patient registry and clinical trial matchmaking program to accelerate clinical trial recruitment, and led worldwide efforts to drive high-impact research and drug development. The organization’s work is particularly critical now as revolutionary breakthroughs are available for roughly 90% of the CF population, but those in the outlying 10% that unfortunately do not benefit from these major advances. The work of EE is laser-focused on changing that — and doing it fast, so nobody is left behind